Loading clinical trials...
Loading clinical trials...
A Phase II, Randomized, Double Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo
Conditions
Interventions
AS012
Placebo
Locations
31
United States
Sun Pharma Site 15
Phoenix, Arizona, United States
Sun Pharma Site 02
Bryant, Arkansas, United States
Sun Pharma Site 09
Fremont, California, United States
Sun pharma site 30
Los Angeles, California, United States
Sun Pharma Site 01
Brandon, Florida, United States
Sun Pharma Site 06
Fort Lauderdale, Florida, United States
Start Date
January 13, 2021
Primary Completion Date
May 20, 2022
Completion Date
February 27, 2023
Last Updated
March 10, 2025
NCT07431177
NCT06991972
NCT06511739
NCT06493578
NCT06113328
NCT07058051
Lead Sponsor
Ache Laboratorios Farmaceuticos S.A.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions